Kala Pharmctls (NASDAQ:KALA) – Investment analysts at Wedbush decreased their FY2020 earnings per share estimates for shares of Kala Pharmctls in a report released on Wednesday. Wedbush analyst L. Moussatos now forecasts that the company will post earnings of $2.78 per share for the year, down from their previous estimate of $3.00. Wedbush currently has a “Outperform” rating and a $46.00 price target on the stock. Wedbush also issued estimates for Kala Pharmctls’ FY2021 earnings at $9.50 EPS.

TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/09/14/fy2020-eps-estimates-for-kala-pharmctls-decreased-by-analyst-kala.html.

Several other research firms have also recently weighed in on KALA. Oppenheimer Holdings, Inc. initiated coverage on Kala Pharmctls in a research report on Tuesday, August 15th. They set an “outperform” rating and a $46.00 price objective for the company. Wells Fargo & Company started coverage on Kala Pharmctls in a research note on Monday, August 14th. They set an “outperform” rating and a $24.00 price target on the stock. J P Morgan Chase & Co started coverage on Kala Pharmctls in a research note on Monday, August 14th. They set an “overweight” rating and a $35.00 price target on the stock. Finally, Bank of America Corporation started coverage on Kala Pharmctls in a research note on Monday, August 14th. They set a “buy” rating and a $33.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, Kala Pharmctls currently has an average rating of “Buy” and a consensus price target of $36.80.

Shares of Kala Pharmctls (NASDAQ KALA) traded up 1.83% on Thursday, hitting $26.68. The stock had a trading volume of 158,303 shares. The firm’s 50-day moving average is $21.92 and its 200 day moving average is $20.44. Kala Pharmctls has a 1-year low of $16.38 and a 1-year high of $26.75. The stock’s market cap is $646.38 million.

In other news, major shareholder Associates L.L.C. Cdk purchased 215,000 shares of the stock in a transaction that occurred on Thursday, July 20th. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $3,225,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Orbimed Advisors Llc purchased 319,333 shares of the stock in a transaction that occurred on Tuesday, July 25th. The shares were purchased at an average price of $15.00 per share, for a total transaction of $4,789,995.00. The disclosure for this purchase can be found here. Insiders have purchased 1,282,666 shares of company stock worth $19,239,990 over the last 90 days.

Kala Pharmctls Company Profile

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Receive News & Ratings for Kala Pharmctls Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmctls and related companies with MarketBeat.com's FREE daily email newsletter.